Hepatology Research · 2013 · 28 citations · 15 references
MedicineInfectious DiseasesPathobiologyCarcinogenesisCell SignalingSignal TransductionHepatic PathologyHepatic PathophysiologyHepatocellular CarcinomaLiver CancerLiver DiseaseViral HepatitisFibrotic ChangeHepatitis C InfectionHepatitis C Virus-associated CarcinogenesisSmad Signaling PathwaySustained Virologic Response DurationTumor Suppression MechanismsTumor Suppression PathwaysViral Hepatitis Pathogenesis
AIM: Insight into hepatic fibrogenesis and carcinogenesis (fibro-carcinogenesis) caused by hepatitis C virus (HCV) infection has come from recent analyses of transforming growth factor (TGF)-β signaling. TGF-β type I receptor and pro-inflammatory cytokine-activated kinases differentially phosphorylate Smad2 and Smad3 to create C-terminally (C), linker (L) or dually (L/C) phosphorylated (p) isoforms. This study aimed to elucidate how HCV infection affected hepatic fibro-carcinogenesis, particularly via phospho-Smad signaling. METHODS: We first studied phospho-Smad2/3 positivity of 100 patients in different stages of HCV-related chronic liver disease. To examine changes in phospho-Smad2/3 after HCV clearance, we analyzed 32 paired liver biopsy samples obtained before and after sustained virological response (SVR), dividing patients into two groups: 20 patients not developing hepatocellular carcinoma (HCC) after attaining SVR (non-HCC group), and 12 patients who developed HCC despite SVR (HCC group). RESULTS: Hepatocytic tumor-suppressive pSmad3C signaling shifted to carcinogenic pSmad3L and fibrogenic pSmad2L/C signaling as liver diseases progressed. In the non-HCC group, 13 patients (65%) displayed fibrotic regression and inflammation reduction after SVR. Interestingly, SVR restored cytostatic pSmad3C signaling in hepatocytes, while eliminating prior carcinogenic pSmad3L and fibrogenic pSmad2L/C signaling. In the HCC group, seven patients (58%) displayed unchanged or even progressed fibrosis despite smoothened inflammatory activity, reflecting persistently high numbers of hepatocytes with pSmad3L- and pSmad2L/C-signaling and low pSmad3C-signaling. CONCLUSION: HCV clearance limits fibrosis and reduces HCC incidence by switching inflammation-dependent phospho-Smad signaling from fibro-carcinogenesis to tumor suppression. However, progression to HCC would occur in severely fibrotic livers if an inflammation-independent fibro-carcinogenic process has already begun before HCV clearance.
15
Classification of chronic hepatitis: Diagnosis, grading and staging
Valeer Desmet, Michael A. Gerber, Jay H. Hoofnagle et al. · Hepatology · 1994 · 2.6K citations
Haruhiko Yoshida, Yasushi Shiratori, Mitsuhiko Moriyama et al. · Annals of Internal Medicine · 1999 · 1.1K citations
Medicine, Oncology, Cancer Control +16